SCHEMBL4040092

SCHEMBL4040092

NC(=O)c1ncccc1CNC[C@H](O)[CH]Cc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 1/20 0.37
KDM4E B2RXH2 4/20 0.35
CYP1A2 P05177 2/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 2/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2D6 P10635 1/20 0.34
HIF1A Q16665 1/20 0.34
PKM P14618 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KCNA5 P22460 1/20 0.33
BCHE P06276 1/20 0.33
KMT2A Q03164 1/20 0.33
HPGD P15428 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ASPH Q12797 1/20 0.33
KDM8 Q8N371 1/20 0.33
ANPEP P15144 1/20 0.33
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4045617 0.89 ADRB1 (0.36) RPS6KB1KDM4ECYP1A2MAPTCYP2D6
SCHEMBL4041089 0.78 MEN1 (0.35) RPS6KB1KDM4EBCHEKMT2AANPEP
SCHEMBL4040582 0.77 KIT (0.39) BCHEANPEP
SCHEMBL4044405 0.77 KDM4E (0.37) KDM4EALDH1A1L3MBTL1
SCHEMBL4043224 0.77 BCHE (0.35) CYP1A2CYP2C9CYP2D6BCHEANPEP
SCHEMBL4038669 0.76 CD274 (0.38) CYP1A2ALDH1A1CYP2D6KMT2A
SCHEMBL4036513 0.76 RPS6KB1 (0.40) RPS6KB1KDM4ECYP1A2MAPTALDH1A1
SCHEMBL4047555 0.75 SIRT1 (0.38) RPS6KB1KDM4ECYP1A2MAPTALDH1A1
SCHEMBL5720767 0.75 TXNRD1 (0.39) RPS6KB1KDM4EALDH1A1BCHETDP1
SCHEMBL5219600 0.74 ANPEP (0.46) CYP1A2ALDH1A1CYP2D6BCHEKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612054-B2 Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof NOVARTIS AG (CH) 2009-11-03 US disclosed
EP-1651592-B1 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2009-04-29 EP disclosed
US-20070111991-A1 Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof NOVARTIS AG (CH) 2007-05-17 US disclosed
EP-1651592-A2 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2006-05-03 EP disclosed
WO-2005014517-A2 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111991-A1 Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof APP, BACE1, BCHE RPS6KB1 2266/4885KDM4E 1788/4885CYP1A2 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.